This is a serious lung disease where the air sacs in your lungs get scarred and stiff. Over time, this scarring makes it hard for your lungs to get oxygen into your blood. It usually gets worse slowly over many years.
Every report comes from a Lived member, sent anonymously.
Have you tried Oxygen for Pulmonary Fibrosis?
Pulmonary fibrosis is scarring of the tissue deep in the lungs, around the tiny air sacs where oxygen passes into the blood. As that tissue thickens and stiffens, the lungs expand less easily and oxygen has a harder time getting through. The result is shortness of breath that usually starts with exertion, such as climbing stairs, and over time can appear with ordinary activity or even at rest. A persistent dry cough, tiredness and unintended weight loss are also common. Some people develop clubbing, a widening and rounding of the fingertips. Pulmonary fibrosis is a type of interstitial lung disease, a large family of conditions that inflame or scar the lungs. When no cause can be found, it is called idiopathic pulmonary fibrosis (IPF), which is the most common form and mainly affects people in their 60s and 70s. Fibrosis can also develop as part of another disease or after a harmful exposure. The distinction matters, because it shapes which treatments are used and what the outlook is.
Doctors think the scarring comes from repeated small injuries to the lung that do not heal properly, so the repair process lays down scar tissue instead of normal tissue. In most people, what started that process cannot be identified. When a cause or contributor is found, it often falls into one of a few groups. Autoimmune and connective tissue diseases, such as rheumatoid arthritis, scleroderma and lupus, can scar the lungs. Long-term inhalation of certain dusts, including asbestos and silica, can do the same. Hypersensitivity pneumonitis, an immune reaction to repeatedly breathed-in substances such as mold or bird feathers and droppings, is another important cause. Some medicines, including the heart rhythm drug amiodarone, the antibiotic nitrofurantoin and methotrexate (used for rheumatoid arthritis and some cancers), and radiation treatment to the chest can also lead to fibrosis. Risk is higher with older age, a history of smoking and male sex. Pulmonary fibrosis also runs in some families, and changes in more than 10 genes have been linked to it. Having a risk factor or a relative with the disease raises the chance of developing it, but it does not mean someone will.
Diagnosis starts with symptoms, a careful history of work, hobbies, home environment, medicines and family illness, and a physical exam. Through a stethoscope, scarred lungs often make fine crackling sounds at the bottom of each breath. The key test is a high-resolution computed tomography (CT) scan of the chest, which shows the location and pattern of scarring in detail. A particular honeycomb-like pattern strongly suggests IPF, although some other diseases can look similar. Lung function tests (breathing tests) measure how much air the lungs can hold and how well oxygen moves into the blood. One of the most watched measurements is forced vital capacity (FVC), the amount of air a person can blow out after a full breath. It is reported as a percentage of what is expected for someone of the same age, height and sex, and a falling FVC over time is one of the clearest signs the disease is advancing. Oxygen levels may also be checked at rest and while walking. Blood tests look for autoimmune diseases that can cause scarring. When the picture is still unclear, a doctor may recommend a bronchoscopy, in which a thin tube is passed into the airways to sample fluid or tissue, or a surgical lung biopsy. Because the label idiopathic means other causes have been ruled out, reaching a confident diagnosis can take time and often involves a lung specialist.
There is no cure for pulmonary fibrosis, and existing scar tissue generally does not go away. Treatment aims to slow further scarring, ease symptoms and keep people as active as possible. Antifibrotic medicines are the main drug treatment for IPF. Nintedanib (Ofev) and pirfenidone (Esbriet) slow the rate at which lung function declines and may reduce sudden flare-ups. They do not make breathing better than it was, so the benefit shows up as slower loss rather than feeling stronger. Nerandomilast (Jascayd), a newer tablet that works in a different way, is approved for IPF and can be taken on its own or alongside nintedanib or pirfenidone. For fibrosis that keeps worsening in other conditions, called progressive pulmonary fibrosis, nintedanib and nerandomilast are both approved. Stomach and bowel side effects are the most common problem with all three: diarrhea is especially frequent with nintedanib and nerandomilast, while pirfenidone more often causes nausea and makes the skin burn easily in sunlight. Nintedanib and pirfenidone need regular liver blood tests, and nintedanib can harm a pregnancy, so effective contraception is needed. When fibrosis has a known cause, treating that cause comes first: stopping a responsible medicine, avoiding a trigger such as mold or birds, or treating an autoimmune disease, sometimes with medicines that calm the immune system. Supportive care makes a large difference in daily life. Pulmonary rehabilitation is a supervised program of exercise, breathing techniques and education that improves stamina and helps people manage breathlessness. Oxygen therapy is prescribed when blood oxygen runs low, during exertion, sleep or all day. Vaccines against flu, pneumonia, COVID-19 and respiratory syncytial virus (RSV) help prevent infections that can set the lungs back. For some people with advanced disease, a lung transplant is an option; it requires an evaluation at a transplant center and lifelong medicines afterward to prevent rejection. Palliative care can be added at any stage to help with breathlessness, cough and anxiety.
Pulmonary fibrosis is a long-term condition, and its course is hard to predict. In some people it stays stable for years; in others it worsens over months. Averages for IPF from past decades put survival at a few years from diagnosis, but individual outcomes vary widely and newer treatments have improved the outlook for many. Fibrosis linked to a treatable cause can follow a different, sometimes slower course. Day to day, the main challenge is breathlessness. Many people learn to pace activities, use oxygen when walking or exercising, and plan around stairs, hills, heat and high altitude. Staying physically active within comfortable limits helps preserve strength. Not smoking and avoiding dust, fumes and secondhand smoke protect the lungs that remain. Follow-up usually involves breathing tests every few months, periodic CT scans and blood tests for medicine side effects. These show whether the disease is stable or progressing and guide changes in treatment, including when to consider oxygen or a transplant referral. Some people have sudden flare-ups, called acute exacerbations, which can be serious; they are more common in advanced disease. People with pulmonary fibrosis also have a higher risk of lung cancer and of high blood pressure in the lungs (pulmonary hypertension). Anxiety and low mood are common, and support groups, counseling and early conversations about future care can help.
See a doctor if shortness of breath or a dry cough lasts for weeks or makes everyday tasks harder than they used to be, especially if you have a family history of lung scarring, an autoimmune disease or work exposure to dust. If you have pulmonary fibrosis, contact your care team promptly if breathing or cough becomes noticeably worse over days or weeks, if you develop a fever or chest infection, or if a medicine causes persistent diarrhea, yellowing of the skin or eyes, or dark urine. Call 911 or go to the emergency room for severe or sudden difficulty breathing, sudden chest pain, bluish lips or fingertips, or new confusion.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Pulmonary Fibrosis is like, what's helped you, or ask the community a question.